Future perspectives for hepatocellular carcinoma

HPB

Volumn 5, Issue 4, 2003, Pages 206-213

  Lau, W Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Screening; Viral hepatitis

Indexed keywords

AFLATOXIN; ALCOHOL; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARCINOGEN; CISPLATIN; CYANOGINOSIN; CYTOTOXIC AGENT; DOXORUBICIN; DRINKING WATER; FERRITIN; FLUOROURACIL; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; IODINATED POPPYSEED OIL I 131; LAMIVUDINE; MICROSPHERE Y 90; OLTIPRAZ; PEGINTERFERON; RADIOISOTOPE; RECOMBINANT INTERFERON; RETINOID; RIBAVIRIN; SOMATOSTATIN DERIVATIVE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BODY FLUID; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CHEMOEMBOLIZATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ECHOGRAPHY; ENVIRONMENTAL FACTOR; GENE THERAPY; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MASS SCREENING; META ANALYSIS; MORBIDITY; PARTIAL HEPATECTOMY; PREDICTION; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SUPPORT GROUP; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VACCINATION; WATER CONTAMINATION;

EID: 0346266234     PISSN: 1365182X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651820310016779     Document Type: Review

References (38)

1. Leong ASY. Epidemiology, risk factors, etiology, premalignant lesions and carcinogenesis. In: Leong ASY, Liew CT, Lau JWY, Johnson PJ (eds). Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. London: Arnold, 1999;1-17.
2. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8.
3. Chang MH, Shau WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000;284:3040-2.
4. Chen DS, Hsu NHM, Sung JL, et al. Hepatitis B vaccines: Status report on long-term efficacy. In: Rizzetto M, Purcell RH, Gerin JL, Verme G (eds). Viral Hepatitis and Liver Disease. Turin: Minerva Medica, 1997;635-7.
5. Esteban R. Management of chronic hepatitis B: An overview. Semin Liver Dis 2002;22(Suppl 1):1-6.
6. Zein CO, Zein NN. Advances in therapy for hepatitis C infection. Microbes & Infection 2002;4:1237-46.
7. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
8. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumours by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-7.
9. Sudakin DL. Dietary aflatoxin exposure and chemoprevention of cancer: A clinical review. J Toxicol Clin Toxicol 2003;41:195-204.
10. Tang ZY. Surgical treatment of subclinical cases of hepatocellular carcinoma. In: Okuda K, Ishak KG (eds). Neoplasms of the Liver. Tokyo: Springer, 1987;367-73.
11. Johnson PJ. Presentation and approach to diagnosis. In: Leong ASY, Liew CT, Lau JWY, Johnson PJ (eds). Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. London: Arnold, 1999;19-29.
12. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh Class A cirrhosis. Am J Med 1996;101:422-34.
13. Bolondi L, Sofia S, Siringo S, et al. Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost-effectiveness analysis. Gut 2001;48:251-9.
14. Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: Is it cost-effective? Eur J Cancer Prev 2001;10:111-15.
15. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001;16:553-9.
16. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcome of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
17. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus. Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
18. Johnson PJ, Leung N, Cheng PO et al. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997;75:236-40.
19. Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47:389-99.
20. Sugawara Y, Yamamoto J, Higashi H, et al. Preoperative portal embolization in patients with hepatocellular carcinoma. World J Surg 2002;26:105-10.
21. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: Review of the randomized clinical trials. Lancet Oncol 2002;3:593-603.
22. Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11.
23. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996;14:693-9.
24. Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: A review and look into the future. Ann Surg 2003;237:171-9.
25. Sarin SK, Sreenivas DV, Saraya A, et al. Improved survival with percutaneous ethanol injection in patients with large hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1994;6:999-1003.
26. Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: Transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197:812-8.
27. Mathurin P, Rixe O, Carbonell N, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111-26.
28. Olschewski M, Lencioni R, Allgaier H, et al. A randomized comparison of radiofrequency thermal ablation and percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Proc Am Soc Clin Oncol 2001 abstract 500.
29. Groupe d'Etude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
30. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
31. Madden MV, Krige JE, Bailey S, et al. Randomized trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-600.
32. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
33. Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002;359:1734-9.
34. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42.
35. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intraarterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-7.
36. Lau WY, Ho S, Leung WT, et al. Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intra-arterial infusion of yttrium-90 microspheres. Int J Radiat Oncol Biol Phys 1998;40:583-92.
37. Leung TW, Patt YZ, Lau WY, et al. Complete pathological response is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-81.
38. Mohr L, Geissler M, Blum HE. Gene therapy for malignant liver disease. Expert Opin Biol Ther 2002;2:163-75.